A daily, 5-10 minute, podcast where we talk about risk and investing. Find out more at mattcorc.com or shoot me an email at matt@mattcorc.com. I would love to hear any feedback, including topic suggestions and insurance questions. If you would like to join me on an episode, send me an email.
…
continue reading
We talk about the recent market turmoil and how that will impact investor actions. Will investors stick to their guns or succumb and sell if the market continues to sell off. A few comments on Medtronic’s settlement and how insurance could have been implemented to reduce the financial burden for Medtronic.…
…
continue reading
GE has seen its market cap decrease by over $200B since 2016 and it now trades at around $8. Is this the correct value or should it be higher or perhaps lower?
…
continue reading
Why we changed our name to the MattCorc Podcast. Who is taking the most risk with the Amazon headquarters, Amazon or the local/state government? What is Waymo? The first autonomous ride hailing service is getting ready to launch in Arizona.
…
continue reading
Moderna plans the biggest biotech IPO ever and we learn more about Amarin’s clinical study. Was mineral oil the best choice of placebo? Lessons we can learn from Amarin about D&O insurance.
…
continue reading
1
Herd Mentality. Why D&O benchmarking is a sales ploy. What to use to make a more informed decision.
9:14
I talk about how brokers use benchmarking to sell you more D&O insurance. Brokers take advantage of herd mentality so insurers buy more D&O than they need.
…
continue reading
Cost and its importance are discussed. Minor differences in coverage can cause major headaches when you have a claim.
…
continue reading
Happy national doughnut day! Fewer companies in the S&P are providing negative guidance. What does this mean? How CFOs are protecting their balance sheets in the event their manufacturing is disrupted.
…
continue reading
Why is Aimmune (AIMT) up today? Is it because Halloween reminded investors how many types of candy have peanuts in them? A lesson on how to make sure you aren’t missing significant coverage gaps in your insurance program. Hint: I learned it from checking my kids Halloween candy.
…
continue reading
How my first time swimming in a lap pool in years was a good metaphor for today’s market and some other interesting facts on the financial markets.
…
continue reading
An overview of the President’s drug pricing proposal and what the new California sexual harassment law could mean for your insurance.
…
continue reading
With biotech stocks sinking, the XBI just hit a 52 week low, and interest rates rising will we see an urgency for acquisitions to be done?
…
continue reading
Quick post on why Insurance buying doesn’t need to be so abstract.
…
continue reading
A ton was learned at the MWE life science deal making symposium and here I share that with you.
…
continue reading
A synopsis of DeviceTalks Boston. Pathways to acquisition, hurdles that you might face and how to derisk your company to make it more appealing to investors and acquiring companies.
…
continue reading
What can we learn from the alleged Chinese cyber espionage incident and how cyber insurance could respond.
…
continue reading
I would love to hear whether people believe the pace of biotech IPOs will continue. Hear my thoughts and share yours at mattcorc.com.
…
continue reading
Why D&O Insurance is expensive for life science companies and how the stage your company is in impacts pricing.
…
continue reading
A client had a fire and $250,000 in product was destroyed. Undamaged condemned stock was valued at over $500,000 but there insurance did not cover it. Find out why that should never happen.
…
continue reading
A recap of the Maryland Bio-Tech Conference that I recently attended.
…
continue reading
A recap of the CFO Forum put on by the NJ Tech Council. The speaker was Jim Mastakas who was the CFO of Amneal when they merged with Impax Labs
…
continue reading
The impacts of Hurricane Florence on the property insurance market are discussed
…
continue reading
Why does a pre-clinical company need insurance?
…
continue reading
A quick synopsis of how insurance liability changes as a company enters the realm to an FDA regulated product.
…
continue reading
Where to look for additional coverage in your proprty policy above and beyond replacing your building or contents. Things to be aware of that could reduce coverage.
…
continue reading
I discuss the Abbvie testosterone settlement and the role of product liability insurance could play. Hurricanes and property insurance.
…
continue reading
A recap of Boston Biotech Week and the RESI conference. How insurance can help you stand out with investors.
…
continue reading
An overview of patent insurance and what it can do.
…
continue reading
A discussion on Product Liability insurance in relation to a possible opioid settlement. Wage & Hour lawsuits are on the rise but there is a solution.
…
continue reading
In the wake of an API manufacturer being shut down in China I discuss using insurance to mitigate the cash flow disruption.
…
continue reading
The possible impacts on moving from quarterly to semiannual reporting periods for public companies on the D&O insurance marketplace
…
continue reading
Amicus and Alnylam both got FDA approval last week. Find out how that can change their risk profile.
…
continue reading
I discuss the PGA Championship being cyber extorted, CA Consumer Privacy Act and the role insurance plays in both of these events.
…
continue reading
We discuss Apple hitting the $1 trillion mark, AIG going the other way, government taking your patent and D&O insurance
…
continue reading
I talk about the prevalence of securities class action filings and how D&O can protect you. I also discuss how we should not choose limits solely by what our peers have in place.
…
continue reading
I talk about what we can learn from Sarepta's clinical hold and how they could insure such an event for their commercial product.
…
continue reading
…
continue reading
Today we are reminded, due to the news that Keryx and Akebia are merging, of what happens when you have a supply chain issue.
…
continue reading
Aquinox disaster and what you can do to protect your company from Black Swans.
…
continue reading
Recap of today’s big events. Stryker bidding on Boston Scientific. CRISPR might cause cancer.
…
continue reading
I discuss liability when a digital health product works but something bad happens. Blurring the lines of medtech and digital health.
…
continue reading
A brief review of the 2018 Medtech conference in Minneapolis
…
continue reading
IPO market is healthy. Rockwell Medical and how D&O insurance could provide balance sheet protection
…
continue reading
Keytruda does it again in the clinic and also changes to M&A landscape. What’s going on at Rockwell Medical? Is your product temperature sensitive?
…
continue reading
Quick rundown on FDA related news, Hemophilia news and how right to try could impact the insurance market
…
continue reading
…
continue reading
…
continue reading
Episode 1 - Drug Pricing and Ford
…
continue reading